Early findings from the ongoing MIRACLE clinical trial suggest that the investigational drug annamycin, given with cytarabine, may help more patients with relapsed or refractory acute myeloid leukemia ...
FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.
Dr. Ashkan Emadi, principal investigator of a first-in-world phase 2 clinical trial evaluating subcutaneous Blincyto ...
A new study led by Mass General Brigham suggests that a more proactive, tech-driven approach to palliative care can ...
A new study suggests that a proactive, tech-driven approach to palliative care can significantly improve the lives of children with advanced cancer.
Dr. Shaun P. McKenzie is board certified in general surgery and in surgical oncology, hepatobiliary surgery, and pancreatic surgery. He is a surgical oncologist with Texas Oncology Surgical ...
The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...
The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...
Amid these challenges, many young adults want to continue working or return to their jobs during treatment. Research shows ...
Dr. Shaun P. McKenzie sat down for a two-part interview with CURE to discuss gallbladder cancer awareness during Gallbladder ...
The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.
FDA accepted a new drug application for tirabrutinib in relapsed or refractory PCNSL.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results